Equities

Elion Clean Energy Co Ltd

Elion Clean Energy Co Ltd

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (CNY)6.32
  • Today's Change0.00 / 0.00%
  • Shares traded8.44m
  • 1 Year change-56.77%
  • Beta1.1290
Data delayed at least 15 minutes, as of Sep 30 2016 07:59 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

As of Sep 23, 2016, the consensus forecast amongst 2 polled investment analysts covering Elion Clean Energy Co Ltd advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Nov 30, 2015. The previous consensus forecast advised investors to purchase equity in Elion Clean Energy Co Ltd.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy0
Outperform2
Hold0
Underperform0
Sell0

Dividends

Historical dividend information is not available for Elion Clean Energy Co Ltd.
Div growth (TTM)-2.63%
More ▼

Earnings history & estimates

Elion Clean Energy Co Ltd reported annual 2015 earnings of 0.06 per share on Apr 21, 2016.
Average growth rate-50.00%
More ▼

Revenue history & estimates

Inner Mongolia Elion Clean Energy Company Limited had revenues for the full year 2015 of 8.06bn. This was 32.92% below the prior year's results.
Average growth rate-32.92%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.